Serious liver disease induced by infliximab

Gabriel J. Tobon, Carlos Cañas, Juan Jose Jaller, Juan Carlos Restrepo, Juan Manuel Anaya

Resultado de la investigación: Contribución a RevistaArtículo

116 Citas (Scopus)

Resumen

Infliximab, a chimeric monoclonal antibody that binds the tumor necrosis factor α (TNFα), is used in the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). Previous cases of significant secondary liver disease associated with infliximab treatment have been reported in patients with RA, CD, and psoriatic arthritis. Two additional patients with RA who developed a serious liver disease associated with infliximab treatment are reported here. A 39-year old RA patient was admitted with cholestatic liver disease after 8 months of treatment with infliximab. She had no history of hepatic diseases, exposure to hepatotoxic or illicit drugs, or alcohol abuse. A liver biopsy showed severe ductal proliferation with collapse and enucleation of the hepatocytes. Despite aggressive treatment with oral prednisolone, she developed hepatic failure. On the 45th day, a liver transplant was performed. The second patient, a 54-year old RA patient, was diagnosed with autoimmune hepatitis after 12 infliximab infusions. She fulfilled autoimmune hepatitis type 1 criteria. A liver biopsy disclosed an altered lobulillar structure with chronic inflammation and the formation of collagen bands. She was treated with prednisolone and azatioprine and a complete recovery was noted 1 month later. These cases should alert rheumatologists to the possibility of new adverse reactions (liver injury) associated with the use of TNFα blockers in an autoimmune setting. © Clinical Rheumatology 2006.
Idioma originalEnglish (US)
Páginas (desde-hasta)578-581
Número de páginas4
PublicaciónClinical Rheumatology
DOI
EstadoPublished - abr 1 2007

Huella dactilar

Liver Diseases
Rheumatoid Arthritis
Liver
Autoimmune Hepatitis
Prednisolone
Crohn Disease
Tumor Necrosis Factor-alpha
Biopsy
Therapeutics
Psoriatic Arthritis
Liver Failure
Street Drugs
Alcoholism
Substance-Related Disorders
Hepatocytes
Collagen
Monoclonal Antibodies
Infliximab
Inflammation
Transplants

Citar esto

Tobon, Gabriel J. ; Cañas, Carlos ; Jaller, Juan Jose ; Restrepo, Juan Carlos ; Anaya, Juan Manuel. / Serious liver disease induced by infliximab. En: Clinical Rheumatology. 2007 ; pp. 578-581.
@article{a354fa9dc29148e2a5e398c901438a9c,
title = "Serious liver disease induced by infliximab",
abstract = "Infliximab, a chimeric monoclonal antibody that binds the tumor necrosis factor α (TNFα), is used in the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). Previous cases of significant secondary liver disease associated with infliximab treatment have been reported in patients with RA, CD, and psoriatic arthritis. Two additional patients with RA who developed a serious liver disease associated with infliximab treatment are reported here. A 39-year old RA patient was admitted with cholestatic liver disease after 8 months of treatment with infliximab. She had no history of hepatic diseases, exposure to hepatotoxic or illicit drugs, or alcohol abuse. A liver biopsy showed severe ductal proliferation with collapse and enucleation of the hepatocytes. Despite aggressive treatment with oral prednisolone, she developed hepatic failure. On the 45th day, a liver transplant was performed. The second patient, a 54-year old RA patient, was diagnosed with autoimmune hepatitis after 12 infliximab infusions. She fulfilled autoimmune hepatitis type 1 criteria. A liver biopsy disclosed an altered lobulillar structure with chronic inflammation and the formation of collagen bands. She was treated with prednisolone and azatioprine and a complete recovery was noted 1 month later. These cases should alert rheumatologists to the possibility of new adverse reactions (liver injury) associated with the use of TNFα blockers in an autoimmune setting. {\circledC} Clinical Rheumatology 2006.",
author = "Tobon, {Gabriel J.} and Carlos Ca{\~n}as and Jaller, {Juan Jose} and Restrepo, {Juan Carlos} and Anaya, {Juan Manuel}",
year = "2007",
month = "4",
day = "1",
doi = "10.1007/s10067-005-0169-y",
language = "English (US)",
pages = "578--581",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",

}

Serious liver disease induced by infliximab. / Tobon, Gabriel J.; Cañas, Carlos; Jaller, Juan Jose; Restrepo, Juan Carlos; Anaya, Juan Manuel.

En: Clinical Rheumatology, 01.04.2007, p. 578-581.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - Serious liver disease induced by infliximab

AU - Tobon, Gabriel J.

AU - Cañas, Carlos

AU - Jaller, Juan Jose

AU - Restrepo, Juan Carlos

AU - Anaya, Juan Manuel

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Infliximab, a chimeric monoclonal antibody that binds the tumor necrosis factor α (TNFα), is used in the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). Previous cases of significant secondary liver disease associated with infliximab treatment have been reported in patients with RA, CD, and psoriatic arthritis. Two additional patients with RA who developed a serious liver disease associated with infliximab treatment are reported here. A 39-year old RA patient was admitted with cholestatic liver disease after 8 months of treatment with infliximab. She had no history of hepatic diseases, exposure to hepatotoxic or illicit drugs, or alcohol abuse. A liver biopsy showed severe ductal proliferation with collapse and enucleation of the hepatocytes. Despite aggressive treatment with oral prednisolone, she developed hepatic failure. On the 45th day, a liver transplant was performed. The second patient, a 54-year old RA patient, was diagnosed with autoimmune hepatitis after 12 infliximab infusions. She fulfilled autoimmune hepatitis type 1 criteria. A liver biopsy disclosed an altered lobulillar structure with chronic inflammation and the formation of collagen bands. She was treated with prednisolone and azatioprine and a complete recovery was noted 1 month later. These cases should alert rheumatologists to the possibility of new adverse reactions (liver injury) associated with the use of TNFα blockers in an autoimmune setting. © Clinical Rheumatology 2006.

AB - Infliximab, a chimeric monoclonal antibody that binds the tumor necrosis factor α (TNFα), is used in the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). Previous cases of significant secondary liver disease associated with infliximab treatment have been reported in patients with RA, CD, and psoriatic arthritis. Two additional patients with RA who developed a serious liver disease associated with infliximab treatment are reported here. A 39-year old RA patient was admitted with cholestatic liver disease after 8 months of treatment with infliximab. She had no history of hepatic diseases, exposure to hepatotoxic or illicit drugs, or alcohol abuse. A liver biopsy showed severe ductal proliferation with collapse and enucleation of the hepatocytes. Despite aggressive treatment with oral prednisolone, she developed hepatic failure. On the 45th day, a liver transplant was performed. The second patient, a 54-year old RA patient, was diagnosed with autoimmune hepatitis after 12 infliximab infusions. She fulfilled autoimmune hepatitis type 1 criteria. A liver biopsy disclosed an altered lobulillar structure with chronic inflammation and the formation of collagen bands. She was treated with prednisolone and azatioprine and a complete recovery was noted 1 month later. These cases should alert rheumatologists to the possibility of new adverse reactions (liver injury) associated with the use of TNFα blockers in an autoimmune setting. © Clinical Rheumatology 2006.

U2 - 10.1007/s10067-005-0169-y

DO - 10.1007/s10067-005-0169-y

M3 - Article

SP - 578

EP - 581

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

ER -